Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity

被引:238
作者
Kim, Tae Hyung [1 ]
Jiang, Hai Hua [1 ]
Youn, Yu Seok [2 ]
Park, Chan Woong [1 ]
Tak, Kyung Kook [1 ]
Lee, Seulki [3 ]
Kim, Hyungjun [4 ]
Jon, Sangyong [4 ]
Chen, Xiaoyuan [3 ]
Lee, Kang Choon [1 ]
机构
[1] Sungkyunkwan Univ, Drug Targeting Lab, Coll Pharm, Suwon 440746, South Korea
[2] Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea
[3] NIBIB, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA
[4] Gwangju Inst Sci & Technol, Sch Life Sci, Kwangju 500712, South Korea
关键词
Curcumin; Solubility; Nanoparticle; Human serum albumin; Antitumor; ENDOTHELIAL-CELLS; IN-VIVO; CONTRAST AGENT; CREMOPHOR-FREE; DRUG-DELIVERY; PHASE-I; PACLITAXEL; TRANSPORT; EFFICACY; ABI-007;
D O I
10.1016/j.ijpharm.2010.10.041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Curcumin (CCM), a yellow natural polyphenol extracted from turmeric (Curcuma longa), has potent anticancer properties as has been demonstrated in various human cancer cells. However, the widespread clinical application of this efficient agent in cancer and other diseases has been limited by its poor aqueous solubility and bioavailability. In this study, we prepared novel CCM-loaded human serum albumin (HSA) nanoparticles (CCM-HSA-NPs) for intravenous administration using albumin bound technology. Field emission scanning electron microscopy (FE-SEM) and dynamic light scattering (DLS) investigation confirmed a narrow size distribution in the 130-150 nm range. Furthermore, CCM-HSA-NPs showed much greater water solubility (300-fold) than free CCM, and on storage, the biological activity of CCM-HSA-NPs was preserved with negligible activity loss. In vivo distributions and vascular endothelial cells transport studies demonstrated the superiority of CCM-HSA-NPs over CCM. Amounts of CCM in tumors after treatment with CCM-HSA-NPs were about 14 times higher at 1 h after injection than that achieved by CCM. Furthermore, vascular endothelial cell binding of CCM increased 5.5-fold, and transport of CCM across a vascular endothelial cell monolayer by Transwell testing was 7.7-fold greater for CCM-HSA-NPs than CCM. Finally, in vivo antitumor tests revealed that CCM-HSA-NPs (10 or 20 mg/kg) had a greater therapeutic effect (50% or 66% tumor growth inhibition vs. PBS-treated controls) than CCM (18% inhibition vs. controls) in tumor xenograft HCT116 models without inducing toxicity. We attribute this potent antitumor activity of CCM-HSA-NPs to enhanced water solubility, increased accumulation in tumors, and an ability to traverse vascular endothelial cell. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:285 / 291
页数:7
相关论文
共 37 条
[31]   Loading of curcumin into macrophages using lipid-based nanoparticles [J].
Sou, Keitaro ;
Inenaga, Shunsuke ;
Takeoka, Shinji ;
Tsuchida, Eishun .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 352 (1-2) :287-293
[32]   Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells [J].
Tiruppathi, C ;
Naqvi, T ;
Wu, YB ;
Vogel, SM ;
Minshall, RD ;
Malik, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (20) :7699-7704
[33]   Enzyme catalysis: Tool to make and break amygdalin hydrogelators from renewable resources: A delivery model for hydrophobic drugs [J].
Vemula, Praveen Kumar ;
Li, Jun ;
John, George .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (27) :8932-8938
[34]   Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein [J].
Vogel, SM ;
Minshall, RD ;
Pilipovic, M ;
Tiruppathi, C ;
Malik, AB .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2001, 281 (06) :L1512-L1522
[35]   Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells [J].
Wartlick, H ;
Michaelis, K ;
Balthasar, S ;
Strebhardt, K ;
Kreuter, J ;
Langer, K .
JOURNAL OF DRUG TARGETING, 2004, 12 (07) :461-471
[36]   Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles [J].
Wartlick, H ;
Spänkuch-Schmitt, B ;
Strebhardt, K ;
Kreuter, J ;
Langer, K .
JOURNAL OF CONTROLLED RELEASE, 2004, 96 (03) :483-495
[37]   Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors [J].
Williams, J ;
Lansdown, R ;
Sweitzer, R ;
Romanowski, M ;
LaBell, R ;
Ramaswami, R ;
Unger, E .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :167-172